Fullmax Pacific

Fullmax Pacific Limited is a Hong Kong-based healthcare company that operates as a key subsidiary of China Grand Pharmaceutical and Healthcare Holdings (Grandpharma). The company serves as a strategic vehicle for the licensing, registration, and commercialization of innovative pharmaceutical products within the Greater China region. It is most notably recognized for its partnership with Basilea Pharmaceutica, through which it secured the rights to the advanced cephalosporin antibiotic Zevtera (ceftobiprole). Fullmax Pacific leverages its parent company's extensive regulatory expertise and distribution network to bridge the gap between international drug developers and the Chinese market. Its portfolio primarily focuses on high-need therapeutic areas such as infectious diseases and oncology. By facilitating the entry of novel therapies into Asia, the company plays a vital role in the growth strategy of the Grandpharma group.